SCHEMBL6404588

SCHEMBL6404588

c1ccc(-n2ncc3ccsc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
POLB P06746 1/20 0.40
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
ALDH1A1 P00352 6/20 0.39
NPSR1 Q6W5P4 2/20 0.39
HSD17B10 Q99714 2/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 3/20 0.39
MAPT P10636 3/20 0.39
PAX8 Q06710 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39
MITF O75030 1/20 0.39
S1PR4 O95977 1/20 0.39
THRB P10828 1/20 0.39
XBP1 P17861 1/20 0.39
S1PR1 P21453 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL731133 0.71 KDM4E (0.44) KDM4EPOLBNPC1RAB9AALDH1A1
SCHEMBL10323306 0.70 POLB (0.40) KDM4EPOLBNPC1RAB9AALDH1A1
SCHEMBL729956 0.68 KDM4E (0.56) KDM4ENPC1RAB9AALDH1A1NPSR1
SCHEMBL3174711 0.68
SCHEMBL30270004 0.68 KDM4E (0.56) KDM4ENPC1RAB9AALDH1A1NPSR1
Hydrochloric Acid SCHEMBL3379409 0.67 KDM4E (0.55) KDM4ENPC1RAB9AALDH1A1NPSR1
SCHEMBL5310771 0.64 ADORA3 (0.50) KDM4EPOLBNPC1RAB9AALDH1A1
SCHEMBL25260663 0.64 MAPT (0.52) KDM4EPOLBNPC1RAB9AALDH1A1
SCHEMBL29405125 0.64 MAPT (0.52) KDM4EPOLBNPC1RAB9AALDH1A1
SCHEMBL25257898 0.63 PLA2G10 (0.46) KDM4EPOLBNPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140357662-A1 THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS XENTION LIMITED (GB) 2014-12-04 US disclosed
EP-2780344-A1 THIENO [2, 3 - C]PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2014-09-24 EP disclosed
WO-2013072693-A1 THIENO [2, 3 - C] PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS XENTION LIMITED (GB) 2013-05-23 WO disclosed
US-20050288347-A1 Certain triazole-based compounds, compositions, and uses thereof AGRIUS GROUP, LLC. 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288347-A1 Certain triazole-based compounds, compositions, and uses thereof ABCG2, ATP5ME, DNTT KDM4E 3676/4885POLB 854/4885NPC1 2070/4885
US-20140357662-A1 THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS KCNA3, KCNK3, KCNJ1 KDM4E 1338/4885POLB 4658/4885NPC1 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.